

ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Patient characteristics


Cohort	SLE I	SLE II	SLE III	SLE IV	SLE V	HC I
Individuals #	44	142	92	92	47	100
Age (median, range)	33 (19-61)	48 (20-81)	44 (19-81)	42 (14-73)	44 (25-69)	49 (16-81)
Disease duration (median, range)	7 (0-32)	13 (0-46)	8 (0-43)	4 (0-40)	11 (3-46)	N/A
Gender (% female)	91	87	89	89	95	85
Ethnicity (% white)	36	96	90	90	91	90
SLEDAI (median, range)	2 (0-18)	2 (0-18)	2 (0-12)	8 (2-28)	0 (0-0)	N/A
Active nephritis (%)	13	11	1	31	0	N/A
Nephritis ever (%)	42	35	43	43	38	N/A
- class I (%)	ND	3	0	0	0	N/A
- class II (%)	ND	5	0	0	11	N/A
- class III (%)	ND	18	6	6	0	N/A
- class IV (%)	ND	71	76	76	78	N/A
- class V (%)	ND	3	18	18	11	N/A
Immunosuppressive treatment (%)	55	48	50	40	51	N/A
- Azathioprine (%)	5	23	18	25	33	N/A
- Cellcept (%)	29	14	17	18	10	N/A

- Methotrexate	8	9	0	2	5	N/A
- Rituximab	3	1	0	0	0	N/A
- Cyclosporine	0	1	7	9	5	N/A
Prednisone treatment	52	67	70	68	74	N/A
(%)						
Prednisone dose (median, range)	10 (0-40)	4 (0-30)	5 (0-40)	10 (0-40)	5 (0-18)	N/A
Hydroxychloroquine	92	73	37	30	74	N/A
(%)						
Venous thrombosis (%)	ND	11	17	17	18	N/A
Time since event (years)	ND	8 (1-38)	ND	ND	10 (3-25)	N/A
Arterial thrombosis (%)	ND	15	24	24	18	N/A
Time since event (years)	ND	9 (0-22)	ND	ND	11 (6-17)	N/A
Myocardial infarction	ND	4	9	9	3	N/A
(%)						
Time since event (years)	ND	10 (0-13)	ND	ND	13 (13)	N/A
CVI (%)	ND	8	13	13	13	N/A
Time since event (years)	ND	9 (1-22)	ND	ND	9 (6-17)	N/A

Supplementary Table 2. Patient characteristics Cohort V

Cohort	SLE V Remission	SLE V Higher	P-value
Individuals #	14	33	N/A
Age (median, range)	38.5 (26-64)	45 (25-69)	0.21
Disease duration	15.50 (4-25)	10 (3-46)	0.47
Gender (% female)	80	100	0.06
Ethnicity (% white)	93	91	0.95
SLEDAI	0	0	N/A
Active nephritis (%)	0	0	N/A
Nephritis ever (%)	30	41	0.71
Immunosuppressive treatment (%)	30	59	0.16
- Azathioprine (%)	20	38	0.45
- Cellcept (%)	0	14	0.56
- Methotrexate	0	7	1.00
- Rituximab	0	0	N/A
- Cyclosporine	10	3	0.45
Prednisone treatment (%)	40	86	0.009
Prednisone dose	0 (0-10)	5 (0-18)	<0.05
Hydroxychloroquine (%)	90	69	0.40
Time since last flare (6)	16 (4-24)	11 (1-48)	0.005
Time in clinical remission	12 (2-24)	5 (1-24)	0.03

Supplementary Figure 1. Immune complex-mediated NET formation in SLE. A-C) Correlation analysis for levels of NETs and immune complexes (IC) in cohorts I, III and IV. D-E) SLE patients in cohorts III and IV were stratified based on NET levels and assessed for levels of type I IFN activity. Statistical analyses by Spearman's correlation and Mann-Whitney U test.



Supplementary Figure 2. Levels of NETs are associated with nephritis. A-C) Patients in cohorts I, III and IV were stratified based on history of nephritis and assessed for levels of circulating NETs. D-E) Levels of NETs were analyzed in patients in cohorts III and IV with or without prior anti-C1q antibodies. Statistical analyses by Mann-Whitney U test with * $p < 0.05$ and ** $p < 0.01$.

